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Abstract
The US National Institute of Neurological Disorders and Stroke convened major stakeholders in
June 2012 to discuss how to improve the methodological reporting of animal studies in grant
applications and publications. The main workshop recommendation is that at a minimum studies
should report on sample-size estimation, whether and how animals were randomized, whether
investigators were blind to the treatment, and the handling of data. We recognize that achieving a
meaningful improvement in the quality of reporting will require a concerted effort by
investigators, reviewers, funding agencies and journal editors. Requiring better reporting of animal
studies will raise awareness of the importance of rigorous study design to accelerate scientific
progress.
Dissemination of knowledge is the engine that drives scientific progress. Because advances
hinge primarily on previous observations, it is essential that studies are reported in sufficient
detail to allow the scientific community, research funding agencies and disease advocacy
organizations to evaluate the reliability of previous findings. Numerous publications have
called attention to the lack of transparency in reporting, yet studies in the life sciences in
general, and in animals in particular, still often lack adequate reporting on the design,
conduct and analysis of the experiments. To develop a plan for addressing this critical issue,
the US National Institute of Neurological Disorders and Stroke (NINDS) convened
academic researchers and educators, reviewers, journal editors and representatives from
funding agencies, disease advocacy communities and the pharmaceutical industry to discuss
the causes of deficient reporting and how they can be addressed. The specific goal of the
meeting was to develop recommendations for improving how the results of animal research
are reported in manuscripts and grant applications. There was broad agreement that: (1) poor
reporting, often associated with poor experimental design, is a significant issue across the
life sciences; (2) a core set of research parameters exist that should be addressed when
reporting the results of animal experiments; and (3) a concerted effort by all stakeholders,
including funding agencies and journals, will be necessary to disseminate and implement
best reporting practices throughout the research community. Here we describe the impetus
for the meeting and the specific recommendations that were generated.
Widespread deficiencies in methods reporting
In the life sciences, animals are used to elucidate normal biology, to improve understanding
of disease pathogenesis, and to develop therapeutic interventions. Animal models are
valuable, provided that experiments employing them are carefully designed, interpreted and
reported. Several recent articles, commentaries and editorials highlight that inadequate
experimental reporting can result in such studies being un-interpretable and difficult to
reproduce1–8. For instance, replication of spinal cord injury studies through an NINDS-
funded program determined that many studies could not be replicated because of incomplete
or inaccurate description of experimental design, especially how randomization of animals
to the various test groups, group formulation and delineation of animal attrition and
exclusion were addressed7. A review of 100 articles published in Cancer Research in 2010
revealed that only 28% of papers reported that animals were randomly allocated to treatment
groups, just 2% of papers reported that observers were blinded to treatment, and none stated
the methods used to determine the number of animals per group, a determination required to
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avoid false outcomes2. In addition, analysis of several hundred studies conducted in animal
models of stroke, Parkinson’s disease and multiple sclerosis also revealed deficiencies in
reporting key methodological parameters that can introduce bias6. Similarly, a review of 76
high-impact (cited more than 500 times) animal studies showed that the publications lacked
descriptions of crucial methodological information that would allow informed judgment
about the findings9. These deficiencies in the reporting of animal study design, which are
clearly widespread, raise the concern that the reviewers of these studies could not adequately
identify potential limitations in the experimental design and/or data analysis, limiting the
benefit of the findings.
Some poorly reported studies may in fact be well-designed and well-conducted, but analysis
suggests that inadequate reporting correlates with overstated findings10–14. Problems related
to inadequate study design surfaced early in the stroke research community, as investigators
tried to understand why multiple clinical trials based on positive results in animal studies
ultimately failed. Part of the problem is, of course, that no animal model can fully reproduce
all the features of human stroke. It also became clear, however, that many of the difficulties
stemmed from a lack of methodological rigor in the preclinical studies that were not
adequately reported15. For instance, a systematic review and meta-analysis of studies testing
the efficacy of the free-radical scavenger NXY-059 in models of ischaemic stroke revealed
that publications that included information on randomization, concealment of group
allocation, or blinded assessment of outcomes reported significantly smaller effect sizes of
NXY-059 in comparison to studies lacking this information10. In certain cases, a series of
poorly designed studies, obscured by deficient reporting, may, in aggregate, serve
erroneously as the scientific rationale for large, expensive and ultimately unsuccessful
clinical trials. Such trials may unnecessarily expose patients to potentially harmful agents,
prevent these patients from participating in other trials of possibly effective agents, and
drain valuable resources and energy that might otherwise be more productively spent.
A core set of reporting standards
The large fraction of poorly reported animal studies and the empirical evidence of associated
bias6,10–14,16–20, defined broadly as the introduction of an unintentional difference between
comparison groups, led various disease communities to adopt general21–23 and animal-
model-specific6,24–26 reporting guidelines. However, for guidelines to be effective and
broadly accepted by all stakeholders, they should be universal and focus on widely accepted
core issues that are important for study evaluation. Therefore, based on available data, we
recommend that, at minimum, authors of grant applications and scientific publications
should report on randomization, blinding, sample-size estimation and the handling of all
data (see below and Box 1).
BOX 1
A core set of reporting standards for rigorous study design
Randomization
• Animals should be assigned randomly to the various experimental groups, and
the method of randomization reported.
• Data should be collected and processed randomly or appropriately blocked.
Blinding
• Allocation concealment: the investigator should be unaware of the group to
which the next animal taken from a cage will be allocated.
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• Blinded conduct of the experiment: animal caretakers and investigators
conducting the experiments should be blinded to the allocation sequence.
• Blinded assessment of outcome: investigators assessing, measuring or
quantifying experimental outcomes should be blinded to the intervention.
Sample-size estimation
• An appropriate sample size should be computed when the study is being
designed and the statistical method of computation reported.
• Statistical methods that take into account multiple evaluations of the data should
be used when an interim evaluation is carried out.
Data handling
• Rules for stopping data collection should be defined in advance.
• Criteria for inclusion and exclusion of data should be established prospectively.
• How outliers will be defined and handled should be decided when the
experiment is being designed, and any data removed before analysis should be
reported.
• The primary end point should be prospectively selected. If multiple end points
are to be assessed, then appropriate statistical corrections should be applied.
• Investigators should report on data missing because of attrition or exclusion.
• Pseudo replicate issues need to be considered during study design and analysis.
• Investigators should report how often a particular experiment was performed
and whether results were substantiated by repetition under a range of conditions.
Randomization and blinding
Choices made by investigators during the design, conduct and interpretation of experiments
can introduce bias, resulting in false-positive results. Many have emphasized the importance
of randomization and blinding as a means to reduce bias6,21–23,27, yet inadequate reporting
of these aspects of study design remains widespread in preclinical research. It is important to
report whether the allocation, treatment and handling of animals were the same across study
groups. The selection and source of control animals needs to be reported as well, including
whether they are true littermates of the test groups. Best practices should also include
reporting on the methods of animal randomization to the various experimental groups, as
well as on random (or appropriately blocked) sample processing and collection of data.
Attention to these details will avoid mistaking batch effects for treatment effects (for
example, dividing samples from a large study into multiple lots, which are then processed
separately). Investigators should also report on whether the individuals caring for the
animals and conducting the experiments were blinded to the allocation sequence, blinded to
group allocation and, whenever possible, whether the persons assessing, measuring or
quantifying the experimental outcomes were blinded to the intervention.
Sample-size estimation
Minimizing the use of animals in research is not only a requirement of funding agencies
around the world but also an ethical obligation. It is unethical, however, to perform
underpowered experiments with insufficient numbers of animals that have little prospect of
detecting meaningful differences between groups. In addition, with smaller studies, the
positive predictive value is lower, and false-positive results can ensue, leading to the
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needless use of animals in subsequent studies that build upon the incorrect results28. Studies
with an inadequate sample size may also provide false-negative results, where potentially
important findings go undetected. For these reasons it is crucial to report how many animals
were used per group and what statistical methods were used to determine this number.
Data handling
Common practices related to data handling that can also lead to false positives include
interim data analysis29, the ad hoc exclusion of data30, retrospective primary end point
selection31, pseudo replication32 and small effect sizes33.
Interim data analysis
It is not uncommon for investigators to collect some data and perform an interim data
analysis. If the results are statistically significant in favour of the working hypothesis, the
study is terminated and a paper is written. If the results look ‘promising’ but are not
statistically significant, additional data are collected. This has been referred to as ‘sampling
to a foregone conclusion’ and can lead to a high rate of false-positive findings29,30.
Therefore, sample size and rules for stopping data collection should be defined in advance
and properly reported. Unplanned interim analyses, which can inflate false-positive
outcomes and require unblinding of the allocation code, should be avoided. If there are
interim analyses, however, these should be reported in the publication.
Ad hoc exclusion of data
Animal studies are often complex and outliers are not unusual. Decisions to include or
exclude specific animals on the basis of outcomes (for example, state of health, dissimilarity
to other data) have the potential to influence the study results. Thus, rules for inclusion and
exclusion of data should be defined prospectively and reported. It is also important to report
whether all animals that were entered into the experiment actually completed it, or whether
they were removed, and if so, for what reason. Differential attrition between groups can
introduce bias. For example, a treatment may appear effective if it kills off the weakest or
most severely affected animals whose fates are then not reported. In addition, it is important
to report whether any data were removed before analysis and the reasons for this data
exclusion.
Retrospective primary end-point selection
It is well known that assessment of multiple end points, and/or assessment of a single end
point at multiple time points, inflates the type-I error (false-positive results)31. Yet it is not
uncommon for investigators to select a primary end point only after data analyses. False-
positive conclusions arising from such practices can be avoided by specifying a primary end
point before the study is undertaken, the time(s) at which the end point will be assessed, and
the method(s) of analysis. Significant findings for secondary end points can and should be
reported, but should be delineated as exploratory in nature. If multiple end points are to be
assessed, then appropriate statistical corrections should be applied to control type-I error,
such as Bonferroni corrections31,34.
Pseudo replicates
When considering sample-size determination and experimental design, pseudo-replication
issues need to be considered32. There is a clear, but often misunderstood or misrepresented,
distinction between technical and biologic replicates. For example, in analysing effects of
pollutants on reproductive health, multiple sampling from a litter, regardless of how many
littermates are quantified, provides data from only a single biologic replicate. When biologic
variation in response to some intervention is the variable of interest, as in many animal
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experiments, analysis of samples from multiple litters is essential. The unit of assessment is
the smallest unit (animal, cage, litter) to which the intervention in question can be
independently administered35.
Small effect sizes
A statistically significant result does not provide information on the magnitude of the effect
and thus does not necessarily mean that the effect is robust, which could account for the
poor reproducibility of certain studies36. Therefore, reporting whether results were
substantiated by repetition, preferably under a range of conditions that demonstrate the
robustness of the effect is encouraged. Also, reporting how often the particular experiment
was performed as a means to control for a general tendency to publish only the best results
would strengthen the validity of experimental results. To this end, carefully designed and
powered animal studies should be budgeted for in the grant applications and funding
agencies should consider supporting repetition studies where appropriate.
An important note about exploratory experiments
For the most part, these best practices do not apply to early-stage observational experiments
searching for possible differences among experimental groups. Such exploratory testing is
frequently conducted using a small sample size, does not have a primary outcome and is
often unblinded. However, because such experiments are likely to be subject to many of the
limitations described above, they should be viewed as hypothesis-generating experiments
and interpreted as such. Potential discoveries arising from the exploratory phase of the
research should be supported by follow-up, hypothesis-testing experiments that take into
consideration and adequately report on the core standards detailed above (Box 1).
The path to implementation
Improving the transparency and quality of reporting cannot be achieved by a single party,
but will require cooperation among all stakeholders, including investigators, reviewers,
funding agencies and journals. Calling upon investigators to provide key information about
the design, execution and analysis of animal experiments described in grant applications and
manuscripts and encouraging reviewers to consider these issues in their evaluations should,
over time, increase both the quality and predictive value of preclinical research. Potential
strategies for achieving this goal can be adopted from the clinical trials community, which
also contended with poor reporting and associated bias. Evidence that clinical trials can
yield biased results if they lack methodological rigor37–42 led to the development and
implementation of the CONSORT guidelines for randomized clinical trials (among other
guidelines), now adopted by many clinical journals and funding organizations. These
guidelines require that authors report whether and how their studies were carried out blind
and randomized, how sample size was determined, whether data are missing owing to
attrition or exclusion, and supply information about other important experimental
parameters43–45. Importantly, the guidelines have improved the transparency of clinical
study reporting in journals that have adopted them46–49. Additional evidence for the power
of such guidelines can be deduced from the observation that, although few animal studies
report on randomization, blinding or sample-size determination, most describe compliance
with animal regulations, which is required by journals6,9,10,50,51.
As a first step, we recommend that funding organizations and journals provide reviewers
with clear guidance about core features of animal study design (listed in Box 1). The goal is
not to be prescriptive or proscriptive, but rather to delineate the minimum set of standards
that should routinely be considered in evaluating the appropriateness of a study. Such
guidance would make the task easier for reviewers of manuscripts and grant applications
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who volunteer their time and are often overextended. In addition, investigators and
reviewers should be encouraged to consult published generic and model-specific guidelines
for designing in vivo animal experiments6,21–27,52,53. To assist reviewers, editors and
funding organizations in making sure that applications and manuscripts contain sufficient
information on the core reporting recommendation (Box 1), authors could be asked to
append relevant information on a standardized form that accompanies the submission. This
form could be as simple as a checkbox indicating the page on which the key reporting
standard is addressed. Such a form is currently used by clinical research journals.
In addition to the measures proposed above, better dissemination of knowledge will be
greatly facilitated by addressing publication bias, the phenomenon that few studies showing
negative outcomes are published54–63. Such deficiency in reporting contributes to needless
repetition of similar studies by investigators unaware of earlier efforts60,61. There is a widely
accepted belief that the scientific community, promotions committees, funding agencies and
journals favour positive outcomes, an impression that can lead to bias64. Possible solutions
include incentivizing investigators to publish negative outcomes, supporting studies of
independent replication, encouraging journals to publish a greater number of studies
reporting negative outcomes, creating a database for negative outcomes (analogous to http://
ClinicalTrials.gov/), and linking the raw data to publications.
Change will not occur overnight. The importance of training scientists to properly design
and adequately report animal studies cannot be overstated. Training and education focused
on key features of experimental design should be an ongoing process for both the novice and
veteran involved in biomedical research. Attention to better study design reporting should be
communicated at major meetings, brought to the attention of reviewers, editors and funders,
required by the publishers of peer-review journals, and included in the training program of
graduate and postdoctoral students. Furthermore, good mentorship is crucial for developing
such skills and should be encouraged and rewarded. Rigorous experimental design and
adequate reporting needs to be emphasized across the board and monitored in training grants
awarded by the US National Institute of Health (NIH) and other funding agencies.
Professional societies can also have an important role by highlighting this issue in their
respective communities.
An important gatekeeper of quality remains the peer review of grant applications and journal
manuscripts. We therefore call upon funding agencies and publishing groups to take actions
to reinforce the importance of methodological rigor and reporting. NINDS has begun taking
steps to promote best practices for preclinical therapy development studies. In 2011, a
Notice was published in the NIH Guide encouraging the scientific community to address the
issues described above in their grant applications, in describing both the project being
proposed and the supporting data upon which it is based (http://grants.nih.gov/grants/guide/
notice-files/NOT-NS-11-023.html). Points that should be considered in a well-designed
study are listed on the NINDS website (http://www.ninds.nih.gov/funding/
transparency_in_reporting_guidance.pdf). Furthermore, the reviewers of applications
reviewed by the NINDS Scientific Review Branch are reminded of these issues and asked to
pay careful attention to the scientific premise of the proposed projects.
We believe that improving how animal studies are reported will raise awareness of the
importance of rigorous study design. Such increased awareness will accelerate both
scientific progress and the development of new therapies.
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